Navigation Links
VisEn Medical Raises $5.0 Million in Expanded Series B Financing
Date:4/18/2008

WOBURN, Mass., April 18 /PRNewswire/ -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging, today announced the expansion of its Series B financing. Merck Capital Ventures and Flagship Ventures co-led this $5.0 million expansion of the Series B round, which initially raised $7 million in November 2007, bringing the total Series B financing amount to $12.0 million. VisEn will use the additional financing to further advance its proprietary fluorescence in vivo imaging product pipelines, and to expand its commercial applications and customer support of its marketed products worldwide.

"We are pleased to have Merck Capital and Flagship Ventures deepen and extend their support of our company and our programs," said Kirtland Poss, President and Chief Executive Officer of VisEn Medical. "Based on our progress since the first Series B closing, the results that customers are achieving with our systems and agents, some key new product launches, and the strong commercial traction we are already seeing in 2008, our Board and our investors have decided to increase their support to accelerate our growth."

"We invest in emerging companies with proven technologies that support the pharmaceutical industry," said Per Lofberg, President and Chief Executive Officer of Merck Capital Ventures and a member of the Board of VisEn. "VisEn is a market leader in fluorescence in vivo imaging pre-clinically, and well positioned to advance into human clinical trials with its technology platforms. These translational linkages are of growing importance in the pharmaceutical and healthcare industries, and we are pleased to participate in this opportunity."

Ed Kania, Chairman of VisEn Medical and Managing Partner of Flagship Ventures noted, "We see tremendous value and promise in VisEn's technologies and products, its deep customer relationships with a growing number of leading pharmaceutical companies, and its early progress driving the translation of its preclinical technologies into eventual clinical use. We are pleased to continue our strong support and participation with VisEn in these areas."

About VisEn Medical, Inc.

VisEn Medical, Inc. was founded in 2000 based on fluorescence in vivo imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn develops and commercializes the industry's highest performing fluorescence in vivo imaging technology platforms, from research through medicine. The Company also works directly with large pharmaceutical partners to design ranges of tailored molecular imaging probes and applications that are targeted to their specific research areas. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures, Merck Capital Ventures and The Bollard Group. For further information please visit http://www.visenmedical.com.

About Merck Capital Ventures, LLC

Merck Capital Ventures is a subsidiary of Merck & Co., Inc. founded in November 2000. Merck Capital Ventures (MCV) actively invests in emerging businesses with interesting technology in areas related to the commercialization, distribution and delivery of pharmaceuticals and related healthcare services. The focus of MCV is to invest in technologies that accelerate innovation related to the pharmaceutical business and other sectors of health care delivery. For further information, see http://www.merckcapitalventures.com.

About Flagship Ventures

Flagship Ventures is a leading venture capital firm focused on creating, financing, and building innovative companies. Founded in 2000, Flagship operates from its offices at Kendall Square in Cambridge, MA. With an active portfolio of over 40 companies, the firm's strategy is to balance its investments across three principal business sectors: Life Science / Diagnostics Tools, Energy & Technology Platforms, and Therapeutics. Through its unique venture creation and seed investing programs, Flagship actively participates in developing new ventures that are commercializing many of the leading breakthroughs of our times. For more information, visit http://www.flagshipventures.com.


'/>"/>
SOURCE VisEn Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
2. Aurora St. Lukes Medical Center Installs the Countrys Second-Largest Hyperbaric Chamber
3. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results
4. Correction: Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Inverness Medical Innovations, Inc.
5. IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments
6. Heritage Victor Valley Medical Group Celebrates Earth Day
7. Medical Tourism Association Announces Worlds Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008
8. Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells
9. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
10. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
11. Roseland Medical Center Hosts Recognition Ceremony and Open House
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: